secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2025-11-28T23:59:59+00:00
Accession:  0001171843-25-007654
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical launches AI-powered TULSA-AI Volume Reduction module for BPH; TAM could triple to ~600K patients
--------------------------------------------------------------------------------

- Launched TULSA-AI Volume Reduction module for BPH at RSNA; reduces procedure times and enables same-day stacking.
- CEO Arun Menawat says module could triple total addressable market to ~600,000 patients annually.
- CAPTAIN randomized trial data shows TULSA superior to robotic prostatectomy in blood loss, length of stay, and pain.
- TULSA Procedure is the only incision-free therapy for both prostate cancer and BPH with customizable precision.
- Profound to present new TULSA-PRO data at RSNA and SUO meetings through Dec 5, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325007654/0001171843-25-007654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184325007654/f8k_112825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer